We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




A Type of Stem Cell May Repair Hearts

By HospiMedica staff writers
Posted on 08 Apr 2005
A specific type of human fetal stem cell has shown the ability to co-differentiate simultaneously into both muscle and blood vessel cells, a finding that may help to repair damaged hearts. More...


Although a number of studies have confirmed the ability of bone-marrow-derived stem cells to develop into cardiac tissue cells, in more recent trials these stem cells have not shown the ability to incorporate into ailing heart tissue as robustly as originally expected. The results appeared to indicate that something was missing.

Now researchers have found that a specific type of stem cell, bearing a surface antigen called CD133, is unusually adept at differentiating into a variety of organ-specific cell types. Although cells with this biomarker are rare in adult issues, they are abundant in the fetal liver. Using human fetal liver tissues, the researchers isolated CD133+ stem cells, then bathed them in a culture rich in growth factors and other biochemicals, including vascular endothelial growth factor-A (VEGF-A) and brain-derived neurotrophic factor (BDNF).

The researchers then injected cells derived from both CD133+ and CD133- liver stem cells into mice. The CD133+ stem cells developed into pulsating vascularized cardiomyocytes but the CD133- cells did not. This showed that the CD133+ cells were capable of forming both myocytes and angiogenic cells. Because of the potential for immune-system rejection, cells isolated from a patient's own body are the best choice rather than cells from fetal tissue. For this reason, the researchers are investigating whether adult livers might bear traces of CD133+. Pre-conditioning the cells in the laboratory may help ensure that the cells have the essential biologic cues critical for differentiation. The study results were reported in the March 2005 issue of Circulation.

"All these findings are re-igniting interest in using these biochemically activated stem cells to regenerate vascularized tissue,” said Dr. Shahin Rafii, professor of genetic medicine at Weill Cornell Medical College (New York, NY, USA), who led the study. "Some of our research may even help find new sources of expandable CD133+ stem cells within umbilical cord blood or adult bone marrow, livers, or other organs.”


Related Links:
Weill Cornell Medical College

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.